20 research outputs found
Ribavirin as a First Treatment Approach for Hepatitis E Virus Infection in Transplant Recipient Patients
The hepatitis E virus (HEV) is the major cause of acute hepatitis of viral origin worldwide. Despite its usual course as an asymptomatic self-limited hepatitis, there are highly susceptible populations, such as those with underlying immunosuppression, which could develop chronic hepatitis. In this situation, implementation of therapy is mandatory in the sense to facilitate viral clearance. Currently, there are no specific drugs approved for HEV infection, but ribavirin (RBV), the drug of choice, is used for off-label treatment. Here, we present two cases of chronic HEV infection in transplant patients, reviewing and discussing the therapeutic approach available in the literature. The use of RBV for the treatment of an HEV infection in organ transplant patients seems to be effective. The recommendation of 12 weeks of therapy is adequate in terms of efficacy. Nevertheless, there are important issues that urgently need to be assessed, such as optimal duration of therapy and drug dosage
Accuracy of CEA, Ca 72.4 and y Ca 15.3 levels obtained by endoscopic ultrasound fine needle aspiration (EUS FNA) in the differential diag nosis of cystic pancreatic lesions
Comienzo de hepatitis aguda grave autoinmune refractaria a tratamiento convencional, rescatada con infliximab
Complementary and alternative medicine in inflammatory bowel disease patients: Frequency and risk factors
Tu1486 Mortality in Patients With Chronic Pancreatitis (CP) With and Without Exocrine Pancreatic Insufficiency (EPI)
Mortality in patients with chronic pancreatitis (CP) with and without exocrine pancreatic insufficiency (EPI)
Mortality in patients with chronic pancreatitis (CP) with and without exocrine pancreatic insufficiency (EPI)
Usefulness of qualitative endoscopic ultrasound-guided elastography for the diagnosis of malignancy in mediastinal and intra-abdominal lymph nodes
Mucosal healing in ulcerative colitis: Do Mayo 0 and 1 scores really have the same prognostic value? A prospective observational cohort study
Cholangitis and multiple liver abscesses after percutaneous ethanol injection (PEI) for recurrent hepatocellular carcinoma (HCC) Colangitis y abscesos hepáticos múltiples tras la inyección percutánea de etanol (IPE) en el tratamiento del carcinoma hepatocelular recurrente
Percutaneous ablation procedures are minimally invasive treatments for unresectable early stage hepatocellular carcinoma (HCC). These techniques are usually safe, but rare and even fatal complications have been described. We present a fatal result after percutaneous ethanol injection (PEI) for the treatment of a recurrent HCC in a non-cirrhotic liver, with subsequent development of diffuse cholangitis and multiple liver abscesses. Although percutaneous drainage and intensive antibiotic treatment were employed, the patient finally died. We discuss about the etiology and the physiopathology of this rare complication in which the therapeutic options are limited and usually unsuccessful